ScreenerHero

EDIT Editas Medicine, Inc.

NAS · US · Healthcare · Biotechnology · editasmedicine.com
2.750USD+0.73%Mkt Cap: 422.35M $P/E: —

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap422.35M USD
Enterprise Value223.14M USD
Revenue (TTM)47.01M USD
Gross Profit-37.95M USD
Net Income (TTM)-160.06M USD
Revenue/Share0.46 USD
Last Price2.750 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.62
PEG—
EV/EBITDA-2.75
EV/Revenue4.75
P/S8.92
P/B3.98
EPS (TTM)-0.68
EPS (Forward)-0.75
52W Range
1.66038% of range4.537
52W High4.537 USD
52W Low1.660 USD
Profitability
Gross Margin-80.75%
Oper. Margin-167.31%
EBITDA Margin-172.40%
Profit Margin-395.01%
ROE-586.56%
ROA-85.81%
Growth
Revenue Growth232.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-165.24M USD
CapEx (TTM)607.00K USD
FCF Margin-94.28%
FCF Yield-10.49%
Net Debt-196.13M USD
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity0.66
Current Ratio3.19
Quick Ratio3.13
Book Value/Sh0.69 USD
Cash/Share1.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.900 USD
Upside (mean)+114.5%
Target Range1.000 USD – 15.00 USD
1.000+114.5% to mean15.00
# Analysts10
Ownership
Shares Out.153.58M
Float115.49M
Insiders0.18%
Institutions79.39%
Short Interest
Short Ratio11.1d
Short % Float19.54%
Short % Out.19.51%
Shares Short29.96M
Short (prev mo.)24.69M
Technical
SMA 502.837 (-3.1%)
SMA 2002.640 (+4.2%)
Beta2.00
S&P 52W Chg16.45%
Avg Vol (30d)3.07M
Avg Vol (10d)2.53M
Technical Indicators
RSI (14)49.8
MACD-0.0557
MACD Signal-0.0686
MACD Hist.+0.0129
BB Upper2.963 USD
BB Middle2.704 USD
BB Lower2.444 USD
BB Width19.21%
ATR (14)0.1908 USD
Vol Ratio (20d)0.71x